Business Context and Reporting Period
Evaxion A/S, a clinical-stage TechBio company specializing in AI-Immunology powered vaccines, filed this Form 6-K on December 19, 2025. The filing incorporates a press release regarding an update on the company's collaboration with MSD.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a disclosure of a material event rather than a financial statement.
Material Changes
The primary material change disclosed is the update on the collaboration with MSD concerning the Gonorrhea vaccine candidate EVX-B2. Specifically, Evaxion has retained global rights to this vaccine candidate.
Outlook and Management Commentary
Management highlighted the strategic importance of retaining global rights to the EVX-B2 candidate. The filing does not contain updated financial guidance, specific risk factors, or details on contingencies beyond the context of the collaboration update.
Investor Verification Checklist
- Verify the specific terms of the retained global rights for the EVX-B2 Gonorrhea vaccine candidate.
- Review the full text of the press release (Exhibit 99.1) for details on the future scope of the MSD collaboration.
- Confirm the current clinical development status of the EVX-B2 candidate.
- Check subsequent filings for any financial impact resulting from the change in collaboration terms.